H. Lundbeck A/S

143 articles about H. Lundbeck A/S

• EU Fines H. Lundbeck A/S and Others $195 Million for Blocking Rival Drugs

  6/19/2013

• Following the Announcement 1 May 2013, H. Lundbeck A/S Today Announces the Total Value of the 2013 Long-Term Incentive Programme for Executive Management and Key Employees

  6/7/2013

• Positive Trial Results for Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S's Abilify Maintena in Schizophrenia

  5/22/2013

• H. Lundbeck A/S Release: Vortioxetine, a New Multimodal Agent in Development for the Treatment of Major Depression, Shows Effects on Cognitive Function in Several Preclinical Animal Models

  5/22/2013

• Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S: Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1

  5/21/2013

• H. Lundbeck A/S – Admittance to Trading and Official Listing of New Shares Due to Exercise of Warrants

  5/21/2013

• Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Enter $825 Million Deal for Alzheimer's Drug

  3/27/2013

• Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S Wins Approval for Monthly Abilify Shot

  3/1/2013

• Lennox-Gastaut Syndrome Foundation and H. Lundbeck A/S Announce Scholarship

  1/23/2013

• Patient Groups Give H. Lundbeck A/S Top Marks

  1/14/2013

• H. Lundbeck A/S Appoints New Vice President of Global Pricing and Market Access

  1/11/2013

• Vernalis PLC and H. Lundbeck A/S Achieve Third Research Milestone

  1/2/2013

• H. Lundbeck A/S Invests Significantly in Product Development and Product Launches and Has Consequently Revised Its Financial Plans

  12/19/2012

• H. Lundbeck A/S Receives Positive Opinion for Approval of Selincro (Nalmefene) in the European Union

  12/14/2012

• Genmab A/S Reaches Third Milestone in H. Lundbeck A/S Collaboration

  12/13/2012

• FDA Accepts Takeda Pharmaceutical Co. Ltd. and H. Lundbeck A/S’s Filing for Review of Brintellix (vortioxetine) for the Treatment of Major Depression

  12/13/2012

• H. Lundbeck A/S Release: Third Quarter Report 2012: Vortioxetine Filed in the U.S. and EU – Revenue From New Products Doubled

  11/7/2012

• H. Lundbeck A/S Release: Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)

  5/8/2012

• H. Lundbeck A/S's Selincro Cuts Alcohol Use by 66% in Clinical Trials

  3/6/2012

• Vernalis PLC and H. Lundbeck A/S Achieve Second Research Milestone in Drug Discovery Collaboration

  12/19/2011